- Report
- March 2024
- 184 Pages
Global
From €3237EUR$3,374USD£2,799GBP
€3597EUR$3,749USD£3,111GBP
- Report
- November 2023
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2878EUR$3,000USD£2,489GBP
- Report
- June 2023
- 338 Pages
Global
From €7196EUR$7,500USD£6,223GBP
- Report
- October 2023
- 145 Pages
Global
From €3022EUR$3,150USD£2,614GBP
- Report
- December 2023
- 140 Pages
Global
From €4270EUR$4,450USD£3,692GBP
- Report
- August 2020
- 114 Pages
Global
From €4078EUR$4,250USD£3,526GBP
- Report
- April 2023
- 180 Pages
Global
From €3118EUR$3,250USD£2,697GBP
- Report
- December 2018
- 48 Pages
Global
From €3353EUR$3,495USD£2,900GBP
- Report
- November 2020
- 199 Pages
Global
€4318EUR$4,500USD£3,734GBP
- Report
- October 2018
- 104 Pages
Global
From €2639EUR$2,750USD£2,282GBP
- Report
- January 2021
- 149 Pages
China, Global
From €3000EUR$3,349USD£2,685GBP
- Report
- May 2024
- 50 Pages
Global
From €2543EUR$2,650USD£2,199GBP
Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more